phase 2b/3 funding.

Prana's management problem is funding. The phase 2b and 3 trials will cost > 100 million dollars. They need this funding just as the GFC sucked money from the system and big pharma have completely gone into their shells.

Management is aware that a public share offer may not raise sufficient funds to proceed with a phase 2b trial at the moment.

There is however no doubt that Prana will survive. They are operating on a shoe string budget and Alzheimer's is far too important to let this potential therapy go down the drain. This is a very commited team with many of the "who's who" of alzheimer's research the world over. They have a massive amount of scientific/clinical data supporting their hypothesis and are churning out papers at an pretty astonishing rate.

Unfortunately us shareholders have to remain patient and have faith that management will proceed as soon as they are confident that they have funding available to proceed with a well designed phase 2b trial.